Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mydecine Innovations Group Inc C.MYCO

Alternate Symbol(s):  MYCOF

Healthcare Advertising Agencies
Mydecine Innovations Group Inc. is a Canada-based biopharmaceutical company. The Company’s principal activities are research, drug development and clinical trials of psilocybin products. The Company offers healthcare professionals a variety serotonin-modulating medications by developing drug families derived from Psilocybin and MDMA. The Company is developing several prodrug families, beginning with a psilocybin-derived smoking cessation drug undergoing a NIDA-funded trial at Johns Hopkins University. It is also developing MYCO-006, short-acting chemical analogs derived from MDMA for treating various conditions, including anxiety and pain. It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.


CSE:MYCO - Post by User

Mydecine Innovations Group Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by nikkeron Nov 26, 2016 8:40am
75 Views
Post# 25516630

RE:RE:Confirmation on date

RE:RE:Confirmation on date
2016-1114 - Notice of Distribution - New Age Farm Inc. (NF) Marketwire Follow November 25, 2016 4:16pm Comments Share Share on Facebook Tweet Share on Twitter Share Share on Linkedin +1 Share on Google+ Email Share via Email Print Page TORONTO, ONTARIO--(Marketwired - Nov. 25, 2016) - New Age Farm Inc. ("NF") has announced a distribution of shares of NHS Industries Ltd. to New Age shareholders of record at November 30, 2016. NF will begin trading ex-distribution on November 28, 2016. Symbol: NF Ex-distribution Date: November 28, 2016 Record Date: November 30, 2016 For questions regarding the distribution, refer to the company's press release dated November 10, 2016. FOR FURTHER INFORMATION PLEASE CONTACT: Canadian Securities Exchange (CSE) Listings (416) 367-7340 Listings@thecse.com www.thecse.com View Comments and Join the Discussion!
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities